• Gene fusion; HGNC; 13575; BRD4 + HGNC; 29919; NUTM1; Name(s)=BRD4-NUTM1, BRD4-NUT (PubMed=15994877; PubMed=29348827).
  
• Mutation; HGNC; 11998; TP53; Simple; p.Arg267Gln (c.800G>A); ClinVar=VCV000127823; Zygosity=Homozygous (DepMap).
  

PubMed=10944559; DOI=10.1093/jnci/92.16.1355
Dang T.P., Gazdar A.F., Virmani A.K., Sepetavec T., Hande K.R., Minna J.D., Roberts J.R., Carbone D.P.
Chromosome 19 translocation, overexpression of Notch3, and human lung cancer.
J. Natl. Cancer Inst. 92:1355-1357(2000)

PubMed=15994877; DOI=10.1136/jmg.2004.029686
Haruki N., Kawaguchi K.S., Eichenberger S., Massion P.P., Gonzalez A., Gazdar A.F., Minna J.D., Carbone D.P., Dang T.P.
Cloned fusion product from a rare t(15;19)(q13.2;p13.1) inhibit S phase in vitro.
J. Med. Genet. 42:558-564(2005)

PubMed=20679594; DOI=10.1093/jnci/djq279
Gazdar A.F., Girard L., Lockwood W.W., Lam W.L., Minna J.D.
Lung cancer cell lines as tools for biomedical discovery and research.
J. Natl. Cancer Inst. 102:1310-1321(2010)

PubMed=24736545; DOI=10.1158/0008-5472.CAN-13-2658
Wang R.-R., Liu W., Helfer C.M., Bradner J.E., Hornick J.L., Janicki S.M., French C.A., You J.-X.
Activation of SOX2 expression by BRD4-NUT oncogenic fusion drives neoplastic transformation in NUT midline carcinoma.
Cancer Res. 74:3332-3343(2014)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=29348827; DOI=10.18632/oncotarget.22862
Stirnweiss A., Oommen J., Kotecha R.S., Kees U.R., Beesley A.H.
Molecular-genetic profiling and high-throughput in vitro drug screening in NUT midline carcinoma-an aggressive and fatal disease.
Oncotarget 8:112313-112329(2017)

PubMed=29681454; DOI=10.1016/j.cell.2018.03.028
McMillan E.A., Ryu M.-J., Diep C.H., Mendiratta S., Clemenceau J.R., Vaden R.M., Kim J.-H., Motoyaji T., Covington K.R., Peyton M., Huffman K., Wu X.-F., Girard L., Sung Y., Chen P.-H., Mallipeddi P.L., Lee J.Y., Hanson J., Voruganti S., Yu Y., Park S., Sudderth J., DeSevo C., Muzny D.M., Doddapaneni H., Gazdar A.F., Gibbs R.A., Hwang T.H., Heymach J.V., Wistuba I.I., Coombes K.R., Williams N.S., Wheeler D.A., MacMillan J.B., DeBerardinis R.J., Roth M.G., Posner B.A., Minna J.D., Kim H.S., White M.A.
Chemistry-first approach for nomination of personalized treatment in lung cancer.
Cell 173:864-878.e29(2018)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31803961; DOI=10.1002/jcb.29564
Mulshine J.L., Ujhazy P., Antman M., Burgess C.M., Kuzmin I.A., Bunn P.A. Jr., Johnson B.E., Roth J.A., Pass H.I., Ross S.M., Aldige C.R., Wistuba I.I., Minna J.D.
From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.
J. Cell. Biochem. 121:3986-3999(2020)